Emily M. Leproust, an officer and director of Twist Bioscience Corp, filed a Form 144 notice on November 3, 2026, disclosing a proposed sale of 4,573 shares of Twist Bioscience common stock on NASDAQ with an aggregate market value of $619,191.97.

Key Highlights

  • Proposed sale: 4,573 shares of Twist Bioscience Corp common stock, with an aggregate market value of $619,191.97, according to the filing.
  • Source of shares: The shares were acquired on November 2, 2026, through a restricted stock vesting transaction from the issuer, classified as compensation.
  • Approximate sale date: November 3, 2026, through Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917.
  • Total shares outstanding: 62,707,424 shares of common stock were listed as outstanding at the time of the notice.
  • Prior three-month sales: The filing lists 12 prior sales by Leproust between August 3, 2026 and October 5, 2026, totaling shares across those transactions with gross proceeds including a single transaction of $56,330,878.38 on September 17, 2026.
  • Tax-related purpose: The filing states the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."

Leproust Proposes Sale of Vested Shares at Twist Bioscience

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 3, 2026, Emily M. Leproust, identified as both an officer and a director of Twist Bioscience Corp (NASDAQ:TWST), is proposing to sell 4,573 shares of the company's common stock. The aggregate market value of the proposed sale is listed as $619,191.97. The broker named in the filing is Fidelity Brokerage Services LLC. Twist Bioscience Corp is headquartered at 681 Gateway Blvd., South San Francisco, California 94080.

The filing discloses that the 4,573 shares were acquired on November 2, 2026, through a restricted stock vesting transaction, with the issuer named as the person from whom the shares were acquired. The nature of payment is described as compensation. The filing's remarks section states that the "sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."

The filing also details securities sold by Leproust over the prior three months, listing 12 separate transactions between August 3, 2026 and October 5, 2026. Those transactions include sales of 5,101 shares on August 3 (gross proceeds $435,223.44), 113,318 shares on August 10 ($14,183,062.19), 19,952 shares on August 12 ($2,495,508.37), 6,639 shares on August 21 ($923,261.83), 41,570 shares on August 25 ($6,317,760.97), 2,302 shares on September 8 ($282,280.22), 356,546 shares on September 17 ($56,330,878.38), 1,687 shares on September 21 ($279,183.99), 5,203 shares on September 24 ($922,906.47), 655 shares on October 1 ($131,000.00), 45,736 shares on October 2 ($8,638,789.48), and 4,548 shares on October 5 ($919,373.72).

What Was Disclosed

Twist Bioscience officer and director Emily M. Leproust filed a Form 144 on November 3, 2026, noticing a proposed sale of 4,573 common shares valued at $619,191.97, acquired through a restricted stock vesting on November 2, 2026, with proceeds intended in part to cover tax obligations.